Syros Pharmaceuticals, Inc. (SYRS)
| Previous Close | 5.00 |
| Open | 5.00 |
| Bid | 5.12 x 100 |
| Ask | 5.27 x 300 |
| Day's Range | 5.00 - 5.30 |
| 52 Week Range | 2.09 - 8.17 |
| Volume | |
| Avg. Volume | 200,980 |
| Market Cap | 138.872M |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.81 |
| Earnings Date | May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.25 |
Business WireSyros to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 07, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows:
Business WireSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
CAMBRIDGE, Mass., May 07, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 14, 2024 to report its first quarter 2024 financial results and provide a corporate update.
ZacksWill Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
Femasys (FEMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
